Posted by Michael Wonder on 15 Jun 2023
Amneal receives NDA approval from FDA for Pemrydi RTU, a ready to use oncology injectable
14 June 2023 - Adds first ready to use presentation of key injectable for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma.
Amneal Pharmaceuticals today announced the 505(b)(2) new drug application approval from the US FDA for Pemrydi RTU.
